ReviewPhysiology & behavior2011
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.
Review in Physiology & behavior, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- A systematic review of antipsychotic drug effects on human gene expression related to risk factors for cardiovascular disease.The pharmacogenomics journal · 2014Pooled it
- Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.American journal of physiology. Endocrinology and metabolism · 2018Trial
- Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England) · 2018Trial
- Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes · 2013Trial
- A pumpless liver-adipose model for studying metabolic dysfunction and drug responses.PloS one · 2026Article
- Investigating the Impacts of Diet, Supplementation, Microbiota, Gut-Brain Axis on Schizophrenia: A Narrative Review.Nutrients · 2024Review
- Mechanism and treatments of antipsychotic-induced weight gain.International journal of obesity (2005) · 2023Review
- Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction.Journal of psychopharmacology (Oxford, England) · 2022Article
- Olanzapine-induced lipid disturbances: A potential mechanism through the gut microbiota-brain axis.Frontiers in pharmacology · 2022Article
- The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.Frontiers in psychiatry · 2021Review
- Prevalence and Associated Factors of Dyslipidemia Among Psychiatric Patients on Antipsychotic Treatment at Hawassa University Comprehensive Specialized Hospital.Nutrition and metabolic insights · 2021Article
- Article
- Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics.Medical sciences (Basel, Switzerland) · 2020Review
- Effect of safranal, a constituent of saffron, on olanzapine (an atypical antipsychotic) induced metabolic disorders in rat.Iranian journal of basic medical sciences · 2019Article
- Food craving and consumption evolution in patients starting treatment with clozapine.Psychopharmacology · 2019Observational
- Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism.Frontiers in psychiatry · 2019Article
- Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects.Current neuropharmacology · 2018Review
- Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages.The Journal of clinical investigation · 2017Article
- HFD-induced energy states-dependent bidirectional control of anxiety levels in mice.International journal of obesity (2005) · 2017Article
- Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject.Therapeutic advances in psychopharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The atypical antipsychotics (AAPs) are associated with weight gain and an increased incidence of metabolic disease including type 2 diabetes mellitus. Epidemiological, cross-sectional and prospective studies suggest that two of the AAPs, olanzapine and clozapine, cause the most dramatic weight gain and metabolic impairments including increased fasting glucose, insulin and triglycerides. Relative to the other AAPs, both olanzapine and clozapine exhibit a particularly high antagonistic affinity for histamine and muscarinic receptors which have been hypothesized as mediators of the reported increase in weight and glucose abnormalities. In this article, we review the current evidence for the AAP associated weight gain and abnormal glucose metabolism. We postulate that the effects of the AAPs on food intake and peripheral metabolism are initially independently regulated but with increasing body adiposity, the early AAP-induced impairments in peripheral metabolism will be exacerbated, thereby establishing a vicious cycle such that the effects of the AAP are magnified by the known pathophysiological consequences of obesity. Furthermore, we examine how inhibition of the histaminergic pathway may mediate increases in food intake and the potential role of the vagus nerve in the reported peripheral metabolic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.